- Optician: Not a doctor; makes glasses.
- Optometrist (O.D.): four years of optometry school after college; examines eyes, does vision tests, prescribes glasses and certain medications.
- Ophthalmologist (M.D. or D.O.): a doctor with four years of medical school, plus four additional years of ophthalmology training; diagnoses and treats eye diseases, prescribes and fits glasses.
- Neuro-ophthalmologist (M.D. or D.O.): a neurologist or ophthalmologist (training in either neurology or ophthalmology and then fellowship training in neuro-ophthalmology) who specializes in diseases that affect the visual pathways connecting the eyes to the brain, disorders of the eye muscles or nerves that can cause double vision or other symptoms, eyelid issues, jumping vision or nystagmus, pupillary abnormalities, among others.
I Ask This Of You!
I have Parkinson's diseases and thought it would be nice to have a place where the contents of updated news is found in one place. That is why I began this blog.
I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible.
I am not responsible for it's contents. I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish.
This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns.
Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. I will not accept any information about Herbal treatments curing Parkinson's, dementia and etc. It will go into Spam.
This is a free site for all with no advertisements.
Thank you for visiting!
Friday, July 10, 2015
People who had recently experienced stressful life events like a serious illness, death of a loved one, marital separation or unemployment especially saw a mood boost after outdoor group walks.“We hear people say they feel better after a walk or going outside but there haven’t been many studies of this large size to support the conclusion that these behaviors actually improve your mental health and well-being,” says senior author Sara Warber, M.D., associate professor of family medicine at the U-M Medical School and member of the Institute for Healthcare Policy and Innovation.
When were you diagnosed with Parkinson’s?
“Sometimes he cannot even eat, but other times he can do anything. He’s almost like Superman and Clark Kent” – Tommy, 47
“People don´t understand my speech. I’ve been thrown out of the store because they thought I was drunk” – Heidi, 40
“It’s like with the bullfighter and the bull. When the bull came into the arena, it was him and I. The battle is lifelong and the outcome fair. I know I cannot kill him” – Eivind, 56
EMERYVILLE, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of recruitment of its Phase 3 EASE LID study. EASE LID is a confirmatory trial designed to evaluate the efficacy and safety of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a motor complication associated with the treatment of Parkinson's disease.
- EASED, a randomized, placebo-controlled, multi-center study, evaluated patients with Parkinson's disease experiencing troublesome LID. Patients were randomized to receive placebo or to one of three dose levels of ADS-5102. As previously reported, ADS-5102 at 340 mg/day significantly reduced LID as measured by change in UDysRS over eight weeks versus placebo (primary endpoint, p=0.005). In addition, ADS-5102 increased ON time without troublesome dyskinesia by 3.8 hours, with 2.7 hours coming from a reduction in ON time with troublesome dyskinesia. Data also suggested that ADS-5102 was generally well tolerated and reported adverse events were consistent with Parkinson's disease and the known amantadine safety profile.
- EASE LID 3, which is estimated to enroll approximately 70 patients. The 13-week multi-center, randomized, double-blind, placebo-controlled study will assess the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime. The primary endpoint of EASE LID 3 is a reduction in dyskinesia assessed by changes in UDysRS with a key secondary endpoint being change in ON time without troublesome dyskinesia as measured by patient diaries.
- EASE LID 2, an open-label safety study, which is also open to patients from EASED, EASE LID and EASE LID 3.
CONTACT: For questions, please contact: Julie Wood Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. Phone: 510-450-3528